載入中
HKSEHealthcareMedical - Devices
最新資料
HK$5.89
+HK$0.01 · +0.17%
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
最新資料
HK$5.89
+HK$0.01 · +0.17%
盤中時間採用HKT。市場資料可能有所延遲。
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
日內區間
目前HK$5.89
52週區間
目前HK$5.89
盤中時間採用HKT。市場資料可能有所延遲。
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
日內區間
目前HK$5.89
52週區間
目前HK$5.89
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.45億 CNY | 5.34億 CNY | 4.74億 CNY | 3.96億 CNY | 3.04億 CNY |
| 銷貨成本 | 1.68億 CNY | 1.31億 CNY | 9643.3萬 CNY | 5919.2萬 CNY | 3787.4萬 CNY |
| 毛利 | 4.76億 CNY | 4.03億 CNY | 3.77億 CNY | 3.36億 CNY | 2.66億 CNY |
| 研究與開發 | 2.14億 CNY | 2.17億 CNY | 1.9億 CNY | 1.84億 CNY | 1.41億 CNY |
| 銷售、一般及管理費用 | 1.82億 CNY | 1.58億 CNY | 1.81億 CNY | 1.61億 CNY | 1.58億 CNY |
| 營業費用 | 3.43億 CNY | 3.39億 CNY | 3.52億 CNY | 2.64億 CNY | 2.03億 CNY |
| 利息收入 | 2566.6萬 CNY | 3014.7萬 CNY | 1850.5萬 CNY | 2025.8萬 CNY | 472.5萬 CNY |
| 利息支出 | 938.5萬 CNY | 1150.4萬 CNY | 983.3萬 CNY | 141.5萬 CNY | 382.4萬 CNY |
| 折舊和攤銷 | 5364.4萬 CNY | 4998萬 CNY | 4625.8萬 CNY | 1944萬 CNY | 1240.3萬 CNY |
| 營業利益 | 1.33億 CNY | 6400.7萬 CNY | 2500.9萬 CNY | 7207.5萬 CNY | 6341.9萬 CNY |
| 淨利 | 1.19億 CNY | 5228萬 CNY | 1448.7萬 CNY | 7014.2萬 CNY | −7907.7萬 CNY |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
